NuVasive reports increased net sales in second-quarter 2023 financial results
Click Here to Manage Email Alerts
Key takeaways:
- NuVasive Inc. reported increased net sales for the second quarter of 2023.
- Sales were driven by the adoption of new products and increased procedural volumes.
NuVasive Inc. has announced increased net sales “driven by further adoption of new products and higher procedural volumes in the U.S.,” according to a company press release.
NuVasive announced net sales of $317.8 million for the second quarter of 2023, a 2.4% increase compared with the prior year period. The company also reported a generally accepted accounting principles (GAAP) operating margin of 5.7% and GAAP diluted earnings per share of $0.14, according to the release.
“I'd like to congratulate our team on another solid quarter,” Chris Barry, CEO of NuVasive, said in the release. “Our results reflect the strength of our differentiated product portfolios and continued commercial execution. Looking ahead, we remain excited and committed to combining with Globus Medical. And in doing so, drive value creation for our shareholders as we help change more patient lives around the globe,” Barry added.
Read more about
Click Here to Manage Email Alerts